JIANGSU
Über Jiangsu Hengrui Pharmaceuticals Co.,Ltd
Jiangsu Hengrui Pharmaceuticals Co Ltd is a China-based company mainly engaged in the research, development, production and sales of drugs. The Company focuses on the field of oncology, covering kinase inhibitors, antibody-drug conjugates (ADCs), tumor immunity, hormone receptor regulation, deoxyribonucleic acid (DNA) repair and epigenetics, supportive care and other research areas. The Company's products include anti-tumor, analgesic anesthesia and contrast agents, which are used in autoimmune diseases, metabolic diseases, cardiovascular diseases, infectious diseases, respiratory diseases, blood diseases, pain management, neurological diseases, ophthalmology, nephrology and other fields. The Company mainly conducts its businesses in domestic and foreign markets.
Q3 2025 Jiangsu Hengrui Pharmaceuticals Co Ltd Earnings Presentation (Chinese)
04.11.2025
08:00
Telekonferenzen und Präsentationen zu Gewinnen
Q4 2025 Jiangsu Hengrui Pharmaceuticals Co Ltd Earnings Release
30.03.2026
10:59
Veröffentlichungen von Geschäftszahlen
Q1 2026 Jiangsu Hengrui Pharmaceuticals Co Ltd Earnings Release
23.04.2026
10:59
Veröffentlichungen von Geschäftszahlen
Jiangsu Hengrui Pharmaceuticals Co Ltd Annual Shareholders Meeting
28.04.2026
06:30
Jährliche Aktionärs-Meetings